This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ansell, J. Converging targets: R&D strategies of the top 20 pharmaceutical companies. (Decision Resources, Thame, UK; October 1997).
Brown, P. Scrip Magazine 07/ 08 03–1994 04,
Horrobin, D.F. J. Roy. Soc. Med. 93, 341–345 (2000).
Horrobin, D.F. J. Pharm. Med. 2, 69–80 (1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Horrobin, D. Realism in drug discovery—could Cassandra be right?. Nat Biotechnol 19, 1099–1100 (2001). https://doi.org/10.1038/nbt1201-1099
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1201-1099
This article is cited by
-
The antibiotic resistance crisis, with a focus on the United States
The Journal of Antibiotics (2017)
-
The discovery of first-in-class drugs: origins and evolution
Nature Reviews Drug Discovery (2014)
-
Diagnosing the decline in pharmaceutical R&D efficiency
Nature Reviews Drug Discovery (2012)
-
The evolution of biology
EMBO reports (2008)
-
Integrating cell-level kinetic modeling into the design of engineered protein therapeutics
Nature Biotechnology (2005)